Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha Teknova's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 42.38.
Alpha Teknova's Days Inventory for the
three
months ended in Mar. 2026 was 87.13.
Alpha Teknova's Days Payable for the
three
months ended in Mar. 2026 was 18.74.
Therefore, Alpha Teknova's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 110.77.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Alpha Teknova Cash Conversion Cycle Related Terms
Alpha Teknova Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Alpha Teknova's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TKNO vs AKBA, ORGO, SIGA: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Teknova Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Alpha Teknova's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Alpha Teknova's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Teknova (TKNO) has a Cash Conversion Cycle of 110.77 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Alpha Teknova and its competitors.
Is Alpha Teknova's Cash Conversion Cycle too high?
Alpha Teknova's current Cash Conversion Cycle is 110.77. The Drug Manufacturers industry median Cash Conversion Cycle is 145.92. Alpha Teknova's value of 110.77 is 24.1% below this industry median. Overall, Alpha Teknova has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alpha Teknova's Cash Conversion Cycle compare to AKBA and ORGO?
Alpha Teknova's Cash Conversion Cycle of 110.77 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.92. Alpha Teknova's value of 110.77 is 24.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.92, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Teknova's current Cash Conversion Cycle of 110.77 is 24.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Alpha Teknova and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Teknova's current Cash Conversion Cycle is 110.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Teknova stock overvalued right now?
Based on GuruFocus' analysis, Alpha Teknova (TKNO) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.55, compared to a current price of $5.34 — trading 50.4% above its estimated fair value. The current Cash Conversion Cycle is 110.77 and 24.1% below the Drug Manufacturers industry median of 145.92. Alpha Teknova's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Alpha Teknova (TKNO), the current Cash Conversion Cycle is 110.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpha Teknova (TKNO) Overvalued in 2026?
Based on GuruFocus' analysis, Alpha Teknova stock appears to be overvalued.
The current stock price of $5.34 is trading 50.4% above its estimated GF Value™ of $3.55.
GuruFocus considers Alpha Teknova to be Significantly Overvalued.
Key valuation signals for TKNO:
Cash Conversion Cycle: 110.77
GF Value™: $3.55 vs. price of $5.34 (50.4% above fair value)
Industry Position: 24.1% below the Drug Manufacturers median
No single metric tells the full story. See the TKNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
63GF Score
Get the complete analysis for TKNO
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKNO has been successfully added to your 
